

RECEIVED


Jan '13 05 04:28p

Siemens IPD West CENTRAL FAX CENTER 968 4816

p. 3

JAN 13 2005

Attorney Docket No. 2001P18159US

CERTIFICATE OF FACSIMILE TRANSMISSION	
The undersigned hereby certifies that this document is being facsimile transmitted to the fax number and date given below.	
Facsimile Number:	703-872-9306
No. of Page:	33 pages total
Date:	01/13/05
By Raquel West:	

UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Fhelmansarai, et al.

Serial No.: 10/039,607

Examiner: Church, Craig E

Filed: October 26, 2001 Group Art Unit: 2882

Title: X-Ray Therapy Electronic Portal Imaging System and Method for Artifact Reduction

Mail Stop RCE

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is submitted:

- ☒ under 37 CFR 1.97 (b), or
(Within three months of filing national application; or date of entry of international application; or before mailing date of first office action on the merits; whichever occurs last)
- ☐ under 37 CFR 1.97 (c) together with either a:
☐ Certification under 37 CFR 1.97 (e), or
☐ A \$240.00 fee under 37 CFR 1.17 (p) authorized to be charged to Deposit Account 19-2179. At any time during the pendency of this application, please charge any fees required or credit any overpayment to Deposit Account 19-2179 pursuant to 37 CFR 1.25.
 (After the CFR 1.97 (b) time period, but before final action or notice of allowance, whichever occurs first)
- ☐ under 37 CFR 1.97 (d) together with a:
☐ Certification under 37 CFR 1.97 (e), and
☐ a petition under 37 CFR 1.97 (d) (2) (ii), required with fee under 37 CFR 1.17(i)(1)
 (Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)
- ☐ under 37 CFR 1.97 (i)
☐ Filed after payment of issue fee, but before grant of patent - No fee or certification required

Applicants submit herewith Form PTO 1449 - Information Disclosure Citation together with copies of patents, publications or other information of which applicant(s) are aware, which applicant(s) believe(s) may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56.

☐ A concise explanation of the relevance of foreign language patents, foreign language publications and other foreign language information listed on PTO Form 1449, as presently understood by the individual(s) designated in 37 CFR 1.56 (c) most knowledgeable about the content that is given on the attached sheet or by the enclosed English-language search report.

☐ The undersigned hereby certifies under 37 CFR 1.97(e)(1) that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or

Page 2 of 3

[] The undersigned certifies under 37 CFR 1.97(e)(2) that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 1.56(c) more than three months prior to the filing of the information disclosure statement.

[X] Applicants do not believe any fee is due. However, at any time during the pendency of this application, please charge any fees required or credit any overpayment to Deposit Account 19-2179 pursuant to 37 CFR 1.25. A duplicate copy of this sheet is enclosed.


The filing of this information disclosure statement shall not be construed as a representation that a search has been made or that no other material information exists. Further, the filing of this information disclosure statement shall not be construed as an admission against interest in any manner or as an admission that the information cited is, or is considered to be material to patentability.

It is requested that the information disclosed herein be made of record in this application.

PLEASE MAIL CORRESPONDENCE TO:

Siemens Corporation
Customer No. 28524
Attn: Elsa Keller, Legal Administrator
170 Wood Avenue South
Iselin, NJ 08830

Respectfully submitted,


Anand Sethuraman, Reg. No. 43,351
ON BEHALF OF
Jenny G. Ko, Reg. No. 44,190
Attorney(s) for Applicant(s)
Telephone: 650-943-7554
Date: 1/13/05

FORM PTO-1449	SERIAL NO. 10/039,607	CASE NO. 2001P18159US
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	FILING DATE 10/26/2004	GROUP ART UNIT 2882
(use several sheets if necessary)		APPLICANT(S): Farhad A. Ghelmansarai, et al.

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER <small>Number-Kind Code (if known)</small>	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
	A1	20030083564	May 1, 2003	Ghelmansarai et al.		

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER <small>Number-Kind Code (if known)</small>	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES OR NO

EXAMINER INITIAL	OTHER ART - NON PATENT LITERATURE DOCUMENTS <small>(Include name of author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published.)</small>					
	A4	"Megavoltage Cone-Beam Computed Tomography Using a High-Efficiency Image Receptor," by Ed J. Seppi et al. Ginzton Technology Center, Varian Medical Systems, Mountain View, CA; Int. J. Radiation Oncology Biol. Phys., Vol. 55, No. 3, pg. 793-803; 2003.				
	A5	"Introduction of a Novel Dose Saving Acquisition Mode for the Portal Vision™ aS500 EPID to Facilitate On-Line Patient Setup Verification," by D Vetterli et al.; Med. Phys. 31 (4), April 2004; 2004 Am. Assoc. Phys. Med; pgs. 828-831.				
	A6	"Preclinical Studies of Megavoltage Cone Beam CT Systems for Tumor Localization in Gated Radiotherapy of Lung Cancer," by Gig S. Mageras et al.; Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA and Ginzton Technology Center, Varian Medical Systems, Mountain View, CA; XIVth ICCR; May 10-13, 2004 Seoul, Korea.				

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Rev. Feb.-97

\\fsv11\common\csummerfield\1287 SIEMENS ONCOLOGY\1287-13\1287-13 PTO Form-1449 10-29-04.doc